according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Betamethasone / Gentamicin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2 H319: Causes serious eye irritation. Reproductive toxicity, Category 1B H360D: May damage the unborn child.

Specific target organ toxicity - repeated H372: Causes damage to organs through pro-

exposure, Category 1 longed or repeated exposure.

Long-term (chronic) aquatic hazard, Cat- H410: Very toxic to aquatic life with long lasting

egory 1 effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

!



Signal word : Danger

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Hazard statements : H319 Causes serious eve irritation.

H360D May damage the unborn child.

H372 Causes damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P337 + P313 If eye irritation persists: Get medical advice/

attention.

P391 Collect spillage.

Hazardous components which must be listed on the label:

betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Propan-2-ol	67-63-0 200-661-7 603-117-00-0	Flam. Liq. 2; H225 Eye Irrit. 2; H319 STOT SE 3; H336	>= 10 - < 20
Methyl p-Hydroxybenzoate	99-76-3 202-785-7	Aquatic Chronic 2; H411	>= 1 - < 2,5

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Contemioin	1402 66 2	Popr 14: U260D	> = 0.02E
Gentamicin	1403-66-3 215-765-8	Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 ————————————————————————————————————	>= 0,025 - < 0,1
betamethasone	378-44-9 206-825-4	aquatic toxicity): 1 Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1.000 specific concentration limit STOT RE 1; H372 >= 0,01 % Repr. 1B; H360D >= 0,01 %	>= 0,025 - < 0,1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 28.09.2024 5345529-00014 Date of first issue: 09.12.2019 5.1

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks Causes serious eye irritation.

May damage the unborn child.

Causes damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5345529-00014 Date of first issue: 09.12.2019

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propylene glycol	57-55-6	TWA	25 ppm 79 mg/m3	FOR-2011- 12-06-1358
Propan-2-ol	67-63-0	TWA	100 ppm 245 mg/m3	FOR-2011- 12-06-1358
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB 2)	Internal

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

	Further information: OTO			
betamethasone	378-44-9	TWA	1 μg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 μg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects Value	
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
Propan-2-ol	Workers	Inhalation	Long-term systemic effects	500 mg/m3
	Workers	Skin contact	Long-term systemic effects	888 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	89 mg/m3
	Consumers	Skin contact	Long-term systemic effects	319 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	26 mg/kg bw/day
Methyl p- Hydroxybenzoate	Workers	Inhalation	Long-term systemic effects	58,76 mg/m3
	Workers	Skin contact	Long-term systemic effects	9,8 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	14,49 mg/m3
	Consumers	Skin contact	Long-term systemic effects	4,2 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	4,16 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry weight (d.w.)
	Marine sediment	57,2 mg/kg dry weight (d.w.)
	Soil	50 mg/kg dry weight (d.w.)
Propan-2-ol	Fresh water	140,9 mg/l
	Marine water	140,9 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5345529-00014 Date of first issue: 09.12.2019

	Intermittent use/release	140,9 mg/l
	Sewage treatment plant	2251 mg/l
	Fresh water sediment	552 mg/kg dry
		weight (d.w.)
	Marine sediment	552 mg/kg dry
		weight (d.w.)
	Soil	28 mg/kg dry
		weight (d.w.)
	Oral (Secondary Poisoning)	160 mg/kg food
Methyl p-Hydroxybenzoate	Fresh water	2,4 μg/l
	Freshwater - intermittent	0,112 mg/l
	Marine water	0,24 μg/l
	Sewage treatment plant	2 mg/l
	Fresh water sediment	0,0632 mg/kg dry
		weight (d.w.)
	Marine sediment	0,00632 mg/kg
		dry weight (d.w.)
	Soil	0,0115 mg/kg dry
		weight (d.w.)

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5345529-00014 Date of first issue: 09.12.2019

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Vapour pressure : No data available

Relative density : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5345529-00014 Date of first issue: 09.12.2019

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Components:

Propan-2-ol:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 25 mg/l

Exposure time: 6 h
Test atmosphere: vapour

Acute dermal toxicity : LD50 (Rabbit): > 5.000 mg/kg

Methyl p-Hydroxybenzoate:

Acute oral toxicity : LD50 (Rat, male): 2.100 mg/kg

Method: OECD Test Guideline 401

Gentamicin:

Acute oral toxicity : LD50 (Rat): 8.000 - 10.000 mg/kg

LD50 (Mouse): 10.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0,2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of :

administration)

LD50 (Rat): 67 - 96 mg/kg

Application Route: Intravenous

LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg Application Route: Intravenous

betamethasone:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,4 mg/l

Exposure time: 4 h

Skin corrosion/irritation

Not classified based on available information.

Components:

Propan-2-ol:

Species : Rabbit

Result : No skin irritation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Methyl p-Hydroxybenzoate:

Species : Rabbit

Result : No skin irritation

Gentamicin:

Species : Rabbit

Result : Mild skin irritation

betamethasone:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Propan-2-ol:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Methyl p-Hydroxybenzoate:

Species : Rabbit

Result : No eye irritation

Gentamicin:

Species : Rabbit

Result : Mild eye irritation

betamethasone:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Propan-2-ol:

Test Type : Buehler Test Exposure routes : Skin contact Species : Guinea pig

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Method : OECD Test Guideline 406

Result : negative

Methyl p-Hydroxybenzoate:

Test Type : Maurer optimisation test

Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Gentamicin:

Remarks : No data available

betamethasone:

Exposure routes : Dermal Species : Guinea pig Result : Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

Propan-2-ol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Methyl p-Hydroxybenzoate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: positive

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 478

Result: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intravenous injection

Result: negative

betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

Propan-2-ol:

Species : Rat

Application Route : inhalation (vapour)

Exposure time : 104 weeks

Method : OECD Test Guideline 451

Result : negative

Gentamicin:

Carcinogenicity - Assess- : No data available

ment

Reproductive toxicity

May damage the unborn child.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Components:

Propan-2-ol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Methyl p-Hydroxybenzoate:

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Result: negative

Gentamicin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Fertility: NOAEL: 20 mg/kg body weight

Result: No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: NOAEL: 3,6 mg/kg body weight

Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 75 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: foetal mortality, No malformations were observed.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

betamethasone:

Effects on foetal develop-

ment

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 0,05 mg/kg body weight Result: Fetotoxicity, Malformations were observed.

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 0,42 mg/kg body weight

Result: Malformations were observed.

Species: Mouse

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 1 mg/kg body weight

Result: Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Propan-2-ol:

Assessment : May cause drowsiness or dizziness.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Gentamicin:

Target Organs : Kidney, inner ear

Assessment : Causes damage to organs through prolonged or repeated

exposure.

betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood,

Adrenal gland

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Propan-2-ol:

Species : Rat NOAEL : 12,5 mg/l

Application Route : inhalation (vapour)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Exposure time : 104 Weeks

Methyl p-Hydroxybenzoate:

Species : Rat
NOAEL : 250 mg/kg
LOAEL : 1.000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days

Method : OECD Test Guideline 407

Gentamicin:

Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney

Symptoms : Vomiting, Salivation

Species : Monkey
LOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Weeks

Target Organs : Kidney, inner ear

Species : Monkey
LOAEL : 6 mg/kg
Application Route : Intramuscular
Exposure time : 3 Weeks

Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat
NOAEL : 5 mg/kg
LOAEL : 10 mg/kg
Application Route : Intramuscular
Exposure time : 52 Weeks
Target Organs : Kidney, Blood

Species : Rat

NOAEL : 12,5 mg/kg
LOAEL : 50 mg/kg
Application Route : Intramuscular
Exposure time : 13 Weeks
Target Organs : Kidney

betamethasone:

Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d

Target Organs : Pituitary gland, Immune system, muscle

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5345529-00014 Date of first issue: 09.12.2019

Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Dog LOAEL : 0,05 mg/kg Application Route : Oral Exposure time : 28 d

Target Organs : Blood, thymus gland, Adrenal gland

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Gentamicin:

Ingestion : Target Organs: Kidney

Target Organs: inner ear

Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal

deafness

betamethasone:

Inhalation : Target Organs: Adrenal gland

Skin contact : Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Propan-2-ol:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 28.09.2024 5345529-00014 Date of first issue: 09.12.2019 5.1

Toxicity to fish LC50 (Pimephales promelas (fathead minnow)): 9.640 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10.000 mg/l

Exposure time: 24 h

Toxicity to microorganisms EC50 (Pseudomonas putida): > 1.050 mg/l

Exposure time: 16 h

Methyl p-Hydroxybenzoate:

LC50 (Oryzias latipes (Japanese medaka)): 59,5 mg/l Toxicity to fish

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 11,2 mg/l

Exposure time: 48 h Method: ISO 6341

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): 91

ma/l

Exposure time: 72 h Method: ISO 8692

EC10 (Pseudokirchneriella subcapitata (green algae)): 31 mg/l

Exposure time: 72 h Method: ISO 8692

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,024 mg/l Exposure time: 70 d

Species: Danio rerio (zebra fish)

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,2 mg/l

Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Gentamicin:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 86 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 10 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1,5

μg/l

Exposure time: 72 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5345529-00014 Date of first issue: 09.12.2019

Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4,7 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1,6 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

100

Toxicity to microorganisms : EC50 : 288,7 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

M-Factor (Chronic aquatic

toxicity)

: 1

betamethasone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): > 50 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,052 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

NOEC: 0,07 µg/l Exposure time: 219 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 229

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 8 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic : 1.000

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

toxicity)

12.2 Persistence and degradability

Components:

Propan-2-ol:

Biodegradability : Result: rapidly degradable

BOD/COD : BOD: 1,19 (BOD5)

COD: 2,23 BOD/COD: 53 %

Methyl p-Hydroxybenzoate:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 89 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Gentamicin:

Biodegradability : Result: rapidly degradable

Biodegradation: 100 % Exposure time: 28 d

Method: OECD Test Guideline 314

12.3 Bioaccumulative potential

Components:

Propan-2-ol:

Partition coefficient: n- : log Pow: 0,05

octanol/water

Methyl p-Hydroxybenzoate:

Partition coefficient: n- : log Pow: 1,98

octanol/water

Gentamicin:

Partition coefficient: n- : log Pow: < -2

octanol/water

betamethasone:

Partition coefficient: n- : log Pow: 2,11

octanol/water

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5345529-00014 Date of first issue: 09.12.2019

very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(betamethasone)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(betamethasone)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

N.O.S.

(betamethasone)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(betamethasone)

IATA : Environmentally hazardous substance, liquid, n.o.s.

(betamethasone)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 964

aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen-

ger aircraft)

964

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5345529-00014 Date of first issue: 09.12.2019

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 3

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 5345529-00014 Date of first issue: 09.12.2019

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) on substances that deplete the ozone : Not applicable

layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2

E1 ENVIRONMENTAL 100 t 200 t

HAZARDS

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H225 : Highly flammable liquid and vapour.

H319 : Causes serious eye irritation.

H330 : Fatal if inhaled.

H336 : May cause drowsiness or dizziness. H360D : May damage the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H400 : Very toxic to aquatic life.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

Date of last issue: 06.07.2024 Version Revision Date: SDS Number: 28.09.2024 5345529-00014 Date of first issue: 09.12.2019 5.1

H410 Very toxic to aquatic life with long lasting effects. H411 Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. Acute toxicity

Aquatic Acute Short-term (acute) aquatic hazard Aquatic Chronic Long-term (chronic) aquatic hazard

Eye Irrit. Eye irritation Flammable liquids Flam. Liq. Repr. Reproductive toxicity

STOT RE Specific target organ toxicity - repeated exposure STOT SE Specific target organ toxicity - single exposure

FOR-2011-12-06-1358 Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / Long term exposure limit

TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sheet

Sources of key data used to : compile the Safety Data

cy, http://echa.europa.eu/

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 5345529-00014
 Date of first issue: 09.12.2019

Classification of the mixture: Classification procedure:

Eye Irrit. 2 H319 Calculation method Repr. 1B H360D Calculation method STOT RE 1 H372 Calculation method Aquatic Chronic 1 H410 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN